Aurora Cannabis (ACB) Stock Price, News & Analysis

Company Overview

Aurora Cannabis Inc., together with its subsidiaries, engages in the production, distribution, and sale of cannabis and cannabis-derivative products in Canada and internationally. It operates through two segments, Canadian Cannabis and Plant Propagation. The company offers medical and consumer cannabis products; supplies propagated vegetables and ornamental plants; and distributes and sells hemp-derived cannabidiol (CBD) products. The company also cultivates and sells dried cannabis, cannabis oils, capsules, edible cannabis, cannabis extracts, and soft gels, which are ingested in various ways, including smoking, vaporizing, and consumption in the form of oil, capsules, dried flowers, vapes, dried milled strains, edibles, concentrates, and strain specific cannabis oils and extracts; and provides patient counseling and outreach services. Its adult-use brand portfolio includes Aurora Drift, San Rafael '71, Daily Special, Whistler, Being, and Greybeard, as well as CBD brands, Reliva and KG7; and medical cannabis brands include MedReleaf, CanniMed, Aurora, Whistler Medical Marijuana Co, Pedanios, Bidiol, and CraftPlant. The company was founded in 2013 and is headquartered in Edmonton, Canada.

Key Stats

• Today's Range: C$5.76 to C$6.22
• 50-Day Range: C$5.83 to C$8.46
• 52-Week Range: C$3.84 to C$12.85
• Volume: 462,991 shs
• Average Volume: 986,951 shs
• Market Capitalization: C$336.16 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: C$5.85
• Consensus Rating: Moderate Buy

Aurora Cannabis Stock Analysis - MarketRank™

Aurora Cannabis scored higher than 6% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Aurora Cannabis has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on 1 buy rating, 3 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Aurora Cannabis has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Aurora Cannabis is -9.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Aurora Cannabis is -9.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Aurora Cannabis has a P/B Ratio of 0.60. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for ACB.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Aurora Cannabis does not currently pay a dividend.

Dividend Growth

Aurora Cannabis does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Short Interest

There is no current short interest data available for ACB.

News and Social Media

• Score: 1.5 / 5
• News Sentiment: -0.34

News Sentiment

Aurora Cannabis has a news sentiment score of -0.34. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.60 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 10 news articles for Aurora Cannabis this week, compared to 2 articles on an average week.

Search Interest

Only 17 people have searched for ACB on MarketBeat in the last 30 days. This is a decrease of -15% compared to the previous 30 days.

MarketBeat Follows

1 people have added Aurora Cannabis to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Aurora Cannabis insiders have sold more of their company's stock than they have bought. Specifically, they have bought C$0.00 in company stock and sold C$59,382.00 in company stock.

Percentage Held by Institutions

Only 13.38% of the stock of Aurora Cannabis is held by institutions.

ACB Stock Analysis - Frequently Asked Questions

How have ACB shares performed this year?

Aurora Cannabis' stock was trading at C$0.65 at the beginning of the year. Since then, ACB shares have increased by 846.2% and is now trading at C$6.15.
View the best growth stocks for 2024 here.

How were Aurora Cannabis' earnings last quarter?

Aurora Cannabis Inc. (TSE:ACB) issued its earnings results on Monday, May, 15th. The company reported ($0.01) EPS for the quarter, meeting analysts' consensus estimates of ($0.01). The business had revenue of $5.18 million for the quarter, compared to analyst estimates of $7.44 million. Aurora Cannabis had a negative trailing twelve-month return on equity of 6.13% and a negative net margin of 11.53%.

How do I buy shares of Aurora Cannabis?

Shares of ACB stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

What other stocks do shareholders of Aurora Cannabis own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Aurora Cannabis investors own include Canopy Growth (CGC), Canopy Growth (WEED), Aphria (APHA), Meta Platforms (META), NVIDIA (NVDA), Organigram (OGI) and Aurora Cannabis (ACBFF).

Company Calendar

• Last Earnings: 5/15/2017
• Today: 12/21/2024

Industry, Sector and Symbol

• Stock Exchange: TSE
• Sector: Medical
• Industry: Drug Manufacturers - Specialty & Generic
• Sub-Industry: N/A
• Current Symbol: TSE:ACB
• CUSIP: N/A
• CIK: N/A
• Web: auroramj.com
• Phone: +1-604-3625207
• Fax: N/A
• Employees: 1,073
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: C$5.85
• High Stock Price Target: C$9.00
• Low Stock Price Target: C$0.80
• Potential Upside/Downside: -4.9%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.60
• Research Coverage: 5 Analysts

Profitability

• EPS (Most Recent Fiscal Year): C($0.63)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: C$-30,320,000.00
• Net Margins: -11.53%
• Pretax Margin: N/A
• Return on Equity: -6.13%
• Return on Assets: -1.87%

Debt

• Debt-to-Equity Ratio: 16.95
• Current Ratio: 3.76
• Quick Ratio: 2.48

Sales & Book Value

• Annual Sales: C$278.98 million
• Price / Sales: 1.20
• Cash Flow: C$4.94 per share
• Price / Cash Flow: 1.25
• Book Value: C$10.28 per share
• Price / Book: 0.60

Miscellaneous

• Outstanding Shares: 54,660,000
• Free Float: N/A
• Market Cap: C$336.16 million
• Optionable: Not Optionable
• Beta: 2.71